Objective To explore the therapeutic efficacy and safety of mannital combined with dopamine for the treatment of refractory ascites in cirrhosis.Methods 92 patients with refractory ascites in cirrhosis were randomly divided in to two groups.The control group (n=42) was given dopamine 40mg by 0.5-2?g/ (kg/min) intravenous drip and furosemide 40mg by intravenous injection.The treatment group (n=50) was given 20% mannital 250ml, furosemide 40mg by intravenous drip and dopamine 40mg by 0.5-2?g/ (kg/min) speed intravenous drip.The conventional treatment was also administered for both groups.Clinical data including main symptoms and signs, daily amount of urine, ascites retrogression situation, complications and adverse drug reactions were monitored.Results The treatment efficacy was higher (86%) in the treatment group than the control group (61.9%) (p<0.01) .The 1st and 2nd weeks of daily average urine output was higher in the treatment group than the control group (p<0.01) .There was no significant difference in blood chemistry and kidney function tests between the two groups (p>0.05) .No remarkable adverse effect was observed.Conclusion Mannital combined with dopamine is clinically effective and safe in treating refractory ascites in cirrhosis patients.
DownLoad: